← board
PTIX
distress 5/10 · elevated risk$0.220%today-95% from 52w high
Revenue
pre-revenue
Liquidity
$4M
Runway
1.1 yrs
Shares 1y
-5%
Price & events
-62.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+0.0%
1D
-16.9%
1W
-52.0%
1M
-68.7%
3M
-62.5%
6M
-93.5%
1Y
-97.8%
2Y
-99.8%
5Y
-99.8%
All
Overview
- Market Cap
- $391.00K
- Volume
- 0
- 52 Week Range
- $0.19 – $4.51
- Total Shares
- 1.81M
- Short %
- 3.30%
- % Held by Insiders
- 3.84%
- % Held by Institutions
- 4.64%
Pipeline · 0 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| No pipeline trials tracked. | |||||
Catalyst news & presentations · 6
- first quarter of 2026trial initiationsecondaryPhase 2PT00114 · Phase 2 efficacy studies plannedSEC 8-K
- 2025-11-20withdrawalNasdaq issued delisting determination due to non-compliance with minimum stockholders' equity and timely filing rulesSEC 8-K
- Q3 2025trial initiationsecondaryPhase 2PT00114 · Initiation of Phase IIa studySEC 8-K
- end of September 2025readoutPhase 1PT00114 · Topline safety data anticipatedSEC 8-K
- Q2 2025readoutPhase 1PT00114 · Public availability of results from multiple dose portion of Phase I studySEC 8-K
- Q4 2024trial initiationsecondaryPhase 1PT00114 · Commence multiple dose portion of Phase I studySEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors
- none identified
Recent news
- 2026-07-14Enterprise value to EBIT forward of Protagenic Therapeutics, Inc. – OTC:PTIX - TradingView
- 2026-07-13Price to earnings forward of Protagenic Therapeutics, Inc. – OTC:PTIX - TradingView
- 2026-06-30Protagenic’s PT00114 calms chronic stress in rats as rival drug fails - Stock Titan
- 2026-06-30Protagenic Therapeutics (PTIX) Unveils Promising Data for PT0011 - GuruFocus
- 2026-06-30Protagenic Therapeutics (NASDAQ: PTIX) delays 10-K; expects filing within 15 days - Stock Titan
- 2026-06-18Protagenic Therapeutics Inc (PTIX) Valuation: PE, PB & Fair Value Analysis - TradingKey
- 2026-06-18Protagenic Therapeutics Inc (PTIX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
- 2026-06-18Protagenic Therapeutics Inc (PTIX) Institutional Confidence - TradingKey
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.